Foley Partner Mark Waxman was quoted in an article titled “What impact will Obama administration have on human subjects research?” in the February 1, 2010 issue of IRB Advisor. Waxman discusses proposed changes to the health care industry under the Obama administration, stating that a possible change would be the lifting of the ban on federal funding of stem cell research and an increase in the number of stem cell trials. He adds that two bills to watch are the Fair Access to Clinical Trials act, which would strengthen a national data base of clinical trials information, and the Physician Payments Sunshine Act of 2008, which calls for transparency in physician relationships with pharmaceutical and device companies.
Related News
March 4, 2026
In the News
Christopher Ward Analyzes Uncertain Future of State Captive‑Audience Laws
Foley & Lardner LLP partner Christopher Ward was quoted in the Law360 article, “State Captive Audience Bans Live On Despite Uncertainty,” analyzing the legal status and future prospects for state laws restricting captive audience meetings.
March 3, 2026
In the News
Patrick Daugherty Assesses Growing Popularity of Crypto ATMs
Foley & Lardner LLP partner Patrick Daugherty assessed the growing popularity of crypto ATMs in the C-Store Dive article, “Navigating the pros and cons of crypto ATMs for convenience retailers.”
March 3, 2026
In the News
Judith Waltz Weighs CMS Anti‑Fraud Tools, Provider Screening, and Moratorium Risks
Foley & Lardner LLP partner Judith Waltz was quoted in the Report on Medicare Compliance article, “Attestation May Send Some PBDs Packing; ‘They May Find Things Have Eroded Over Time’,” discussing the evolving anti-fraud ecosystem, the Centers for Medicare & Medicaid Services' (CMS) forthcoming provider screening tool, and benefits of moratorium.